These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38173839)

  • 1. Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
    Cheng Y; Yuan X; Tian Q; Huang X; Chen Y; Pu Y; Long H; Xu M; Ji Y; Xie J; Tan Y; Zhao X; Song H
    Front Oncol; 2023; 13():1334938. PubMed ID: 38173839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
    Cheng Y; Yuan X; Tian Q; Huang X; Chen Y; Pu Y; Long H; Xu M; Ji Y; Xie J; Tan Y; Zhao X; Song H
    Front Oncol; 2022; 12():951589. PubMed ID: 36620535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
    Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
    Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
    Shen M; Liu S; Stoyanova T
    Am J Clin Exp Urol; 2021; 9(1):73-87. PubMed ID: 33816696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
    Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
    Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC
    Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A literature review of the promising future of
    Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
    Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
    Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.
    Mao Y; Wang X; Zheng F; Wang C; Tang Q; Tang X; Xu N; Zhang H; Zhang D; Xiong L; Liang J; Zhu J
    Oncotarget; 2016 Apr; 7(17):24810-23. PubMed ID: 27050150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
    Xu C; Zhu M; Wang Q; Cui J; Huang Y; Huang X; Huang J; Gai J; Li G; Qiao P; Zeng X; Ju D; Wan Y; Zhang X
    J Nanobiotechnology; 2023 Nov; 21(1):410. PubMed ID: 37932752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TROP2 conjugated hollow gold nanospheres as a novel nanostructure for targeted photothermal destruction of cervical cancer cells.
    Liu T; Tian J; Chen Z; Liang Y; Liu J; Liu S; Li H; Zhan J; Yang X
    Nanotechnology; 2014 Aug; 25(34):345103. PubMed ID: 25102337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
    Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
    Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
    Govindan SV; Cardillo TM; Rossi EA; Trisal P; McBride WJ; Sharkey RM; Goldenberg DM
    Mol Pharm; 2015 Jun; 12(6):1836-47. PubMed ID: 25402018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
    Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
    Front Oncol; 2021; 11():796625. PubMed ID: 35059318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 17. Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
    Oncotarget; 2020 Mar; 11(10):942. PubMed ID: 32206190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells.
    Tan X; Fang P; Li K; You M; Cao Y; Xu H; Zhu X; Wang L; Wei X; Wen H; Li W; Shi L; Sun X; Yu D; Zhu H; Wang Z; Liu D; Shen H; Zhou W; An M
    MAbs; 2023; 15(1):2220466. PubMed ID: 37314961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Directional conjugation of Trop2 antibody to black phosphorus nanosheets for phototherapy in orthotopic gastric carcinoma.
    Jia L; Fu Y; Zhang N; Liu Y; Su L; Wang H; Zhao W
    Nanomedicine; 2023 Jul; 51():102687. PubMed ID: 37121458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.
    Pommier Y; Thomas A
    Clin Cancer Res; 2023 Mar; 29(6):991-993. PubMed ID: 36637483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.